Publications by authors named "N A Savelov"
Background: Among several treatment options for BRAF-mutant metastatic melanoma, a combination of BRAF inhibitor, MEK inhibitor, and anti-PDL1 antibody seems to be a new emergent approach recently registered in the Russian Federation. It is still not clear which patient population benefits more from this simultaneous use of three drugs instead of its sequencing.
Aim: This study aimed to evaluate patients' characteristics treated in real practice in 14 Russian regions by triple combination and to analyze their outcomes depending on biomarkers (PD-L1 expression).
The article demonstrates a detailed analysis of the results of the rounds of quality control of immunohistochemical studies conducted by the Central Committee of the Immunohistochemical Quality Control Center of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia in 2023. Typical shortcomings and errors in the immunohistochemical examination of various tumors have been identified and ways to eliminate them are given. Particular attention is paid to defining a panel of standard breast cancer markers and eliminating the shortcomings of immunohistochemical examination of markers of accompanying diagnosis.
View Article and Find Full Text PDFPD-L1 immunohistochemistry has been approved as a diagnostic assay for immunotherapy. However, an international comparison across multiple cancers is lacking. This study aimed to assess the performance of PD-L1 diagnostic assays in non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC) and urothelial cancer (UC).
View Article and Find Full Text PDFArticle Synopsis
- PD-L1 testing, crucial for understanding cancer treatment responses, is typically done via immunohistochemistry (IHC), but this study explores how PCR-based measurements of PD-L1 RNA compare with IHC results across different commercial assays.
- In a study of 167 non-squamous non-small cell lung carcinomas, there was moderate correlation between RNA and protein expression, and PCR testing revealed that most tumors classified as PD-L1-low by RNA did not show PD-L1 protein presence according to IHC.
- The findings suggest that while some tumors have high RNA levels of PD-L1, they may not meet IHC cut-offs, indicating the need for further research into whether these differences are due to technical issues or biological
Aim Of Study: To determine a diagnostic algorithm for detecting translocation of the gene and its frequency in the Moscow region.
Materials And Methods: During the priod between 2014 and 2018 (inclusive), 488 patients without activating mutations in the gene in the Moscow region were tested. To detect translocation of the ALK gene, fluorescence hybridization (FISH) methods, an immunohistochemical method, and, in some cases, a polymerase chain reaction were used.